CENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)

Transcription

1 CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS Administered Orally At a Dose Of 50mg Or 70mg Twice Daily Or 100mg Or 140mg Once Daily In Subjects With Chronic Phase Philadelphia Chromosome Or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant Or Intolerant To Imatinib Mesylate (Gleevec ) PROTOCOL NUMBER : CA PRINCIPAL INVESTIGATOR : Priscilla B. Caguioa For more details, click this link TITLE : A Randomised, Open-label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma who are not Eligible for a Bone Marrow Transplant PROTOCOL NUMBER : LYM-3002 CONTACT NUMBER : For more details, click this link &rank=1 TITLE : An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma PROTOCOL NUMBER : MK / ZOLINZA STUDY

2 For more details, click this link TITLE : An Open-label, Dose Escalation, Multicenter Phase 1 /2 Study of KW-2478 Combination with Bortezomib in Subjects with Relapse and/or Refractory Multiple Myeloma PROTOCOL NUMBER : KW INT-001 For more details, click this link 001&rank=1 TITLE : A Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial Comparing The Efficacy Of Bevacizumab In Combination With Rituximab And CHOP (R-CHOP) In Previously Untreated Patients With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) / MAIN PROTOCOL NUMBER : BO20603 For more details, click this link BREAST TITLE : A Randomized, Open-Label, Multicenter, Phase 3 Study Of Epoetin Alfa Plus Standard Supportive Care Versus Standard Support Care In Anemic Patients With Metastatic Breast Cancer Receiving First Line Standard Chemotherapy PROTOCOL NUMBER : EPO-ANE 3010 STUDY COORDINATOR : Cariel Palanca For more details, click this link

3 TITLE : A Randomised, Multicentre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, (ALTTO) their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer PROTOCOL NUMBER : EGF STUDY COORDINATOR : Roxanne Astorga For more details, click this link TITLE : A Phase 3 Randomized, Double-Blind, Placebo Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Pertuzumab+ Trastuzumab+Docetaxel Vs. Placebo+ Trastuzumab + Docetaxel In Previously Untreated Her2-Positive Metastatic Breast Cancer CLEOPATRA Study PROTOCOL NUMBER : WO20698 STUDY COORDINATOR : Irene Guna For more details, click this link TITLE : An International Multi-Center Open-Label 2-Arm Phase III Trial Of Adjuvant Bevacizumab In Triple- Negative Breast Cancer (BEATRICE Study) PROTOCOL NUMBER : BO PRINCIPAL INVESTIGATOR : Charity Charisse Viado-Gorospe, MD STUDY COORDINATOR : Ana Paradiang CONTACT NUMBER : For more details, click this link TITLE : An Open-label Phase 1 Study to Evaluate Initial Pharmacokinetics, Efficacy and Safety for CT- P6 in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer (1.2)CT-P6 PROTOCOL NUMBER : CT-P6 1.2

4 STUDY COORDINATOR : Roselle Bresenio For more details, click this link TITLE : Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study Of Denosumab As Adjuvant Treatment For Women With Early- Stage Breast Cancer At High Risk Of Recurrence (D- CARE) PROTOCOL NUMBER : STUDY COORDINATOR : Roxanne Astorga For more details, click this link TITLE : A Double-blind, Randomised, Parallel Phase 1 Study to Evaluate Initial Comparative Pharmacokinetics, Safety and Efficacy for CT-P6 and Herceptin in Metastatic Breast Cancer (1.3) PROTOCOL NUMBER : CT-P6 1.3 CONTACT NUMBER : For more details, click this link TITLE : Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer (3.1 Study) PROTOCOL NUMBER : CT-P6 3.1 ; Celltrion Inc. STUDY COORDINATOR : Kristine Degollacion For more details, click this link

5 TITLE : An Open Label, Randomised, Parallel Group, Multicenter Study to Compare Zoladex 10.8mg given every 2 weeks with Zoladex 3.6mg given every 4 weeks in Pre-menopausal women with Estrogen Receptor Positive Advanced Breast Cancer/ PRESTIGE Study PROTOCOL NUMBER : D8666C00001 For more details, click this link TITLE : Breast Cancer with Overexpression of ErbB2-Study of the Treatment Paradigm in Metastasis to Brain (BRAINSTORM) PROTOCOL NUMBER : WEUKSTV4109 / For more details, click this link TITLE : Asia Pacific Breast Initiatives 1 (Observational Study Protocol) PROTOCOL NUMBER : DOCET_R_01832 PRINCIPAL INVESTIGATOR : Charity Viado-Gorospe, MD CONTACT NUMBER : GASTROINTESTINAL / COLON TITLE : A Randomized, Double-Blind, Multicentre, Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN,AZD2171) in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination with FOLFOX in Patients with Previously Untreated Metastatic Colorectal Cancer (HORIZON III) PROTOCOL NUMBER : D8480C00013

6 For more details, click this link TITLE : An Asia Pacific Non-Randomized Open-Labeled Phase II Study Evaluating The Safety And Efficacy Of FOLFIRI Plus Cetuximab (Erbitux) Or FOLFOX Plus Cetuximab As First-Line Therapy In Subjects With KRAS Wild-Type Metastatic Colorectal Cancer (APEC Study) PROTOCOL NUMBER : EMR PRINCIPAL INVESTIGATOR : Charity Charisse V. Gorospe, MD STUDY COORDINATOR : Ana Paradiang CONTACT NUMBER : For more details, click this link TITLE : A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated Wild-type KRAS, Metastatic Colorectal Cancer PROTOCOL NUMBER : AMG954 / STUDY COORDINATOR : Pamela Asis For more details, click this link TITLE : Adjuvant Colon Cancer with ELOXatin / 5-FU Based Regimen ACCELOX Registry PROTOCOL NUMBER : ACCELOX Registry PRINCIPAL INVESTIGATOR : Charity Viado-Gorospe, MD STUDY COORDINATOR : Paz Figuerroa CONTACT NUMBER : For more details, click this link TITLE : The Global Observational Registry Collection Longitudinal Data On Advanced GIST Patients

7 (GOLD registry) PROTOCOL NUMBER : CSTI571B2404 ; Novartis Healthcare Philippines CONTACT NUMBER : KIDNEY/RENAL TITLE : Axitinib as Second Line Therapy for Asian Patients with Metastatic Renal Cell Cancer (AG ) PROTOCOL NUMBER : AG (Axitinib) A STUDY COORDINATOR : Pamela Asis (RKL) For more details, click this link %28Axitinib%29+A &rank=1 LIVER TITLE : A Phase III Randomized Study To Evaluate Survival Of Patients Treated With Talaporfin Sodium (LS11) And Interstitial Light Emitting Diodes (LED) As Compared To The Standard Of Care Therapies In The Treatment Of Unresectable Hepatocellular Carcinoma (HCC) PROTOCOL NUMBER : LSO-OL005 PRINCIPAL INVESTIGATOR : Carlos Dy, MD STUDY COORDINATOR : Charlene Ebuenga CONTACT NUMBER : loc For more details, click this link TITLE : A Multicenter, Randomized, Double-blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients with Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib IMCL PROTOCOL NUMBER : CP ; Imclone LLC STUDY COORDINATOR : Pamela Asis

8 For more details, click this link TITLE : GIDEON: Global Investigation of Therapeutic Decision in Hepatocellular Carcinoma and of its Treatment with Nexavar (PMS) PROTOCOL NUMBER : NX0802 PRINCIPAL INVESTIGATOR : Charity Viado- Gorospe, MD CONTACT NUMBER : For more details, click this link LUNG TITLE : Multicenter, Randomized, Double-Blind, Phase III Trial To Investigate The Efficacy And Safety Of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared To Placebo Plus Standard Pemetrexed Therapy In Patients With Stage IIIB/IV Or Recurrent Non Small Cell Lung Cancer After Failure Of First Line Chemotherapy PROTOCOL NUMBER : LUME LUNG/ STUDY COORDINATOR : Megan Aguilar For more details, click this link TITLE : LUX-Lung 3: A Randomised, Open-label, Phase III Study of BIBW 2992 versus Chemotherapy as First-Line treatment for Patients with Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation PROTOCOL NUMBER : STUDY COORDINATOR : Megan Aguilar For more details, click this link TITLE : A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Oral Talactoferrin In Addition To Best Supportive Care In Patients With Non-Small Cell Lung Cancer Who Have Failed Two

9 Or More Prior Treatment Regimens PROTOCOL NUMBER : LF-0207 Fortis-M PRINCIPAL INVESTIGATOR : Dr. Rubi K. Li STUDY COORDINATOR : Pamela Asis For more details, click this link M&rank=1 TITLE : A Randomized, Multicenter, Open-Label, Phase 3 Study Of Gemcitabine-Cisplatin Chemotherapy Plus IMC-11F8 Versus Gemcitabine-Cisplatin Chemotherapy Alone In The First-Line Treatment Of Patients With Squamous Stage Iiib Or IV Non-Small Cell Lung Cancer (NSCLC) IMCL CP (SQUIRE)Darbepoetin Alfa Administered Once-Every-3 Weeks In Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy PROTOCOL NUMBER : IMCLCP PRINCIPAL INVESTIGATOR : Maximino D. Bello III, MD STUDY COORDINATOR : Charlene Ebuenga CONTACT NUMBER : For more details, click this link TITLE : A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500g Once-every-3-weeks in Anemic Subjects with Advanced Stage Non-Small Cell Lung Cancer Receiving Multi-cycle Chemotherapy PROTOCOL NUMBER : STUDY COORDINATOR : Roxanne Astorga For more details, click this link TITLE : Active Implementation of Quality of Life (QOL) Assessment in Patients with Advanced NSCLC and Comparison of QOL and Response Endpoints PROTOCOL NUMBER : DOCET_R_02271 CRA : Paz Figuerroa

10 CONTACT NUMBER : TITLE : Epidermal Growth Factor Receptor (EGFR) Mutation Among Filipino Patients With Advanced Or Metastatic Non Small Cell Lung Cancer (NSCLC) PROTOCOL NUMBER : EGFR PRINCIPAL INVESTIGATOR : Antonio H. Villalon, MD CONTACT NUMBER : loc TITLE : A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Of AMG 706 In Combination With Paclitaxel And Carboplatin For Advanced Non-Small Cell Lung Cancer PROTOCOL NUMBER : STUDY COORDINATOR : Cecille Fernando For more details, click this link OVARIES TITLE : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Assess The Efficacy And Safety Of Weekly Farletuzumab (Morab-003) In Combination With Carboplatin And Taxane In Subjects With Platinum-Sensitive Ovarian Cancer In First Relapse Morab PROTOCOL NUMBER : Morab STUDY COORDINATOR : Roxanne Astorga CONTACT NUMBER : For more details, click this link Others TITLE : Yondelis Post Marketing Surveillance Study PROTOCOL NUMBER : ET743SAR4001

11 PRINCIPAL INVESTIGATOR : Charity Viado Gorospe, MD CONTACT NUMBER : TITLE : Cancer and Its Economic Impact on Households in the ASEAN Countries PROTOCOL NUMBER : ACTION PRINCIPAL INVESTIGATOR : Agnes Gorospe, MD CONTACT NUMBER :